Rockefeller Capital Management’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$463K Buy
21,831
+4,645
+27% +$92.9K ﹤0.01% 2015
2025
Q4
$280K Buy
17,186
+10,830
+170% +$164K ﹤0.01% 2190
2025
Q3
$74.3K Buy
+6,356
New +$82.9K ﹤0.01% 2729
2025
Q1
Sell
-16,705
Closed -$240K 1737
2024
Q4
$240K Sell
16,705
-799
-5% -$12.6K ﹤0.01% 1627
2024
Q3
$395K Buy
17,504
+4,746
+37% +$98.1K ﹤0.01% 1500
2024
Q2
$248K Sell
12,758
-1,288
-9% -$33.7K ﹤0.01% 1593
2024
Q1
$527K Sell
14,046
-4,374
-24% -$192K ﹤0.01% 1456
2023
Q4
$1.03M Buy
18,420
+7,762
+73% +$338K ﹤0.01% 1130
2023
Q3
$440K Sell
10,658
-1,006
-9% -$52.3K ﹤0.01% 1321
2023
Q2
$651K Buy
11,664
+1,165
+11% +$63.1K ﹤0.01% 1243
2023
Q1
$584K Sell
10,499
-1,562
-13% -$72.9K ﹤0.01% 1286
2022
Q4
$439K Buy
12,061
+9,186
+320% +$300K ﹤0.01% 1330
2022
Q3
$81K Buy
2,875
+1,402
+95% +$53.4K ﹤0.01% 2110
2022
Q2
$66K Sell
1,473
-3,835
-72% -$199K ﹤0.01% 2165
2022
Q1
$402K Buy
5,308
+59
+1% +$5.16K ﹤0.01% 1403
2021
Q4
$781K Buy
5,249
+921
+21% +$141K ﹤0.01% 1140
2021
Q3
$629K Sell
4,328
-14,837
-77% -$2.55M ﹤0.01% 1176
2021
Q2
$3.75M Buy
19,165
+9,534
+99% +$1.73M 0.02% 530
2021
Q1
$1.74M Sell
9,631
-3,228
-25% -$557K 0.01% 621
2020
Q4
$1.82M Buy
12,859
+2,639
+26% +$383K 0.01% 545
2020
Q3
$1.27M Buy
10,220
+8,312
+436% +$873K 0.01% 536
2020
Q2
$170K Sell
1,908
-309
-14% -$24.1K ﹤0.01% 1000
2020
Q1
$138K Buy
+2,217
New +$173K ﹤0.01% 921

Other funds holding TXG

Rockefeller Capital Management's TXG Position: Q1 2026 in Review

Rockefeller Capital Management increased its 10x Genomics (TXG) stake by 27% in Q1 2026, buying an estimated $92.9K and bringing the position to 21,831 shares worth $463K. The position accounts for ﹤0.01% of the portfolio, ranked #2015.

Rockefeller Capital Management first reported a position in TXG in Q1 2020 and has held it in 23 quarters since. The position peaked at $3.75M in Q2 2021. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Rockefeller Capital Management held 21,831 shares of 10x Genomics worth $463K as of Q1 2026.
  • Rockefeller Capital Management bought 4,645 10x Genomics shares in Q1 2026, an estimated $92.9K.
  • 10x Genomics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #2015 holding.
  • Rockefeller Capital Management first reported a position in 10x Genomics in Q1 2020 and has held it in 23 quarters since.
  • Rockefeller Capital Management's 10x Genomics position peaked at $3.75M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.